PLAYBOOK · CBD · UK / EU
Card Acquiring for UK and EU CBD Brands
Under Novel Foods regulation
CBD sold for ingestion in the UK and EU sits inside the Novel Foods regime — and that single fact dictates how acquirers underwrite you. UK ingestibles need an FSA application on the public list (Validated or Awaiting Evidence) to remain on sale, while EU sales hinge on national interpretations and the still-pending EFSA opinion that fixed a provisional safe intake of around 2 mg/day for a 70 kg adult. This playbook covers how that regulatory reality flows through to MCCs, reserves, and acquirer appetite.
WHY THIS COMBINATION IS HARD
What goes wrong when generalist acquirers see this profile.
No CBD ingestible holds full Novel Foods authorisation yet
As of 2026, no CBD product has received full UK or EU Novel Foods authorisation — UK ingestibles trade on the FSA public list status (Validated / Awaiting Evidence / Removed), and acquirers treat the entire category as conditionally legal. That conditionality is the single biggest underwriting blocker.
FSA list status drives acquirer KYB
Underwriters now ask for the specific RP number on the FSA register, the application status, and proof your SKUs match the dossier composition. Brands selling SKUs that were removed from the list — or never appeared — are routinely declined or terminated mid-contract.
EFSA's 2 mg/day provisional safe level reshapes EU labelling
EFSA's February 2026 update set a provisional safe intake of roughly 2 mg/day for a 70 kg adult, well below most market dosing. EU acquirers are now flagging SKUs that exceed this level on the label, particularly for cross-border sales into Germany, France, and the Netherlands.
Scheme rules require THC and ingredient transparency
Visa and Mastercard require clear THC content disclosure (under 0.2% / 0.3% as applicable), full ingredient listing, and accessible third-party Certificates of Analysis. Missing or stale COAs are one of the most common reasons existing CBD MIDs are terminated at quarterly review.
MCC misclassification is endemic
Many CBD brands are boarded under generic MCCs (5499, 5912, 5977) without the acquirer flagging the file as a CBD programme internally. When the scheme audit catches this, the MID is closed without notice and added to the MATCH/TMF file — making the next placement materially harder.
Chargebacks above 0.9% trigger Visa VAMP enrolment fast
The category sees elevated dispute rates driven by efficacy expectations ('it didn't work for my pain'), subscription confusion, and friendly fraud. Once a CBD MID crosses Visa's 0.9% or Mastercard's ~1.0% threshold, escalation into monitoring programmes is faster than in lower-risk verticals because the file is already flagged.
WHAT TO EXPECT
Realistic terms for this combination.
ROLLING RESERVE
8-15% rolling reserve held 180 days, occasionally 180-day deferred + cap for newer brands
SETTLEMENT
T+3 to T+7, with T+7 typical for first 90 days
MCC CODES
5499 (ingestibles / specialty food), 5912 (topicals / drug stores), 5977 (cosmetics), 5993 (CBD vape e-liquids)
Scheme reporting: Visa Integrity Risk Programme (VIRP) classifies CBD as a tier-1 high-integrity-risk category requiring registered programmes and enhanced monitoring. Sustained dispute ratios above 0.9% (Visa) or 1.0% (Mastercard) trigger rapid escalation into VAMP / Excessive Chargeback programmes, and a terminated CBD MID is routinely reported to MATCH for five years.
ACQUIRER LANDSCAPE
Who actually underwrites this combination.
The pool splits into three groups: UK-authorised PSPs and acquirers with a documented CBD programme that demands FSA list evidence and current COAs; EU credit institutions in jurisdictions with clearer national CBD positions (notably parts of Central and Western Europe) that accept ingestibles meeting EFSA-aligned dosing; and offshore specialist acquirers used as overflow or backup for SKUs that sit outside the FSA list. Generalist acquirers — including most tier-1 high-street processors — will not board CBD ingestibles at all, regardless of revenue.
HOW ICETREE APPROACHES IT
Our approach for merchants in this combination.
- We pre-screen acquirers for documented CBD programmes that accept FSA Validated or Awaiting Evidence status, so the application is not declined at first read.
- We map every SKU to the right MCC (5499 ingestibles vs 5977 cosmetics vs 5993 vape) before submission — preventing the misclassification terminations that dominate this category.
- We package the underwriting file with the FSA RP number, current third-party COAs, THC test results, and Novel Foods dossier extracts in the format underwriters expect.
- We negotiate reserve and settlement based on your real dispute history and AOV, not the generic 10% / 180-day default applied to unknown CBD files.
- We maintain a primary plus backup acquirer structure so brands are not single-threaded if an acquirer exits the vertical or an FSA list status changes.
FAQ
Common questions answered.
RELATED PLAYBOOKS
Want IceTree on your side?
Run the Approval Predictor for a 2-minute estimate of your acquirer fit, expected reserve range, and what to prepare — specific to United Kingdom / EU and Novel Foods.